• Novartis has committed to making a global donation of up to 130 million doses of the anti-malarial drug hydroxychloroquine to support efforts to fight the COVID-19 pandemic.
• Sandoz, the generics and biosimilars division of Novartis, today begins delivering the first doses of hydroxychloroquine to the Swiss authorities, who are organizing its distribution to hospitals.
• Switzerland becomes the first country in Europe, and the second globally after the USA, to receive a donation of this drug.

Rotkreuz, April 3, 2020 – Today, Novartis, …

• New clinical trial to evaluate Jakavi^® (ruxolitinib) in patients with COVID-19 associated cytokine storm
   
• Cytokine storm is a type of severe immune overreaction that can result from coronavirus infection and may contribute to respiratory compromise in patients with COVID-19^1-3

• Pre-clinical and preliminary clinical evidence suggests Jakavi, a well-established JAK inhibitor, could reduce the number of patients requiring intensive care and mechanical …

• Prespecified analysis of pooled data from ORION-9, -10 and -11 Phase III clinical trials shows inclisiran reduced low-density lipoprotein-cholesterol (LDL-C) by 51% at 17 months¹
   
• Prespecified exploratory analysis based on safety reporting from the three trials, showed fewer major adverse cardiovascular events (MACE) with inclisiran compared to placebo¹
   
• The data are consistent with LDL-C lowering as a strong surrogate for improved patient cardiovascular outcomes² and …

• Zolgensma^® (onasemnogene abeparvovec), a one-time administered gene therapy, has been recommended for European Commission (EC) conditional approval for patients with spinal muscular atrophy (SMA) and a clinical diagnosis of Type 1 or SMA patients with up to three copies of the SMN2 gene
   
• Zolgensma has demonstrated significant and clinically meaningful therapeutic benefit in presymptomatic and symptomatic SMA, including prolonged event-free survival and achievement of motor milestones unseen in natural history of the disease and to date …

Available 24 hours a day or living 24 hours away – the carer of someone with heart failure comes in all guises. But where they are all the same is in the important role they play in helping someone with heart failure live with their condition.

Heart failure is complex. It is debilitating and potentially life-threatening. It causes the heart muscle to become stiff or weak, meaning it’s unable to pump enough blood to meet the demands of the body.¹ This leaves heart failure patients exhausted and short of breath, severely limiting the activities they are able to do.^{1 …}